Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01).
暂无分享，去创建一个
H. Putter | J. Nortier | J. Kroep | V. Smit | H. V. van Laarhoven | L. V. van Warmerdam | M. Wasser | A. Charehbili | C. V. D. van de Velde | E. Maartense | E. Meershoek-Klein Kranenbarg | S. van de Ven | J. Heijns | M. Dercksen | B. Vriens | N. Hamdy | A. E. van Leeuwen-Stok | G. Liefers | C. van de Velde | L. Kessels | M. Pepels